A Phase 1 Dose Escalation and Expansion Study of AK117

Summary

This is a multicenter, open label, single arm, Phase 1，dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacodynamics, PK, immunogenicity, and preliminary antitumor activity of AK117 administered intravenously to adult subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas.

Timeline

Start

2021-03-23

Primary completion

2022-01-25

Completion

2023-05-12

Drugs

Indications